[国民健康保险提供的精准医疗]

[Precision Medicine Provided by National Health Insurance].

作者信息

Muto Manabu, Kondo Tomohiro, Matsubara Junichi, Kanai Masashi, Matsumoto Shigemi, Ashida Kanami, Suga Junko, Mukai Kumi

机构信息

Dept. of Clinical Oncology, Kyoto University Hospital.

出版信息

Gan To Kagaku Ryoho. 2020 Aug;47(8):1158-1163.

PMID:32829347

Abstract

From June 2019, 2 different comprehensive genomic profiling(CGP)test panels were covered by National Health Insurance System in Japan. However, the indication of CGP was solid cancer patients refractory to standard chemotherapy or those without standard of care, while other countries indicate CGP to chemotherapy naIve advanced cancer patients. To be covered by National Health Insurance System, certified core hospital for genomic medicine should hold expert panel with affiliated hospitals. We develop a unique system for expert panel collaborated with SYSMEX Corporation to streamline medical staffs' effort. To provide precision medicine to cancer patients, we have to maximize the merit of CGP and solve several issues.

摘要

自2019年6月起，日本国民健康保险制度涵盖了2种不同的综合基因组分析（CGP）检测面板。然而，CGP的适用对象是对标准化疗难治的实体癌患者或没有标准治疗方案的患者，而其他国家则将CGP应用于未经化疗的晚期癌症患者。为了纳入国民健康保险制度，基因组医学认证核心医院应与附属医院共同组建专家小组。我们与希森美康公司合作开发了一个独特的专家小组系统，以简化医务人员的工作。为了向癌症患者提供精准医疗，我们必须最大限度地发挥CGP的优势并解决若干问题。